Omnicef and Robitussin drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Omnicef (cefdinir) and Robitussin (guaifenesin). Common drug interactions include cardiac failure congestive among females and acute respiratory failure among males.

The phase IV clinical study analyzes what interactions people have when they take Omnicef and Robitussin. It is created by eHealthMe based on reports of 14 people who take the same drugs from the FDA, and is updated regularly.

What is Omnicef?

Omnicef has active ingredients of cefdinir. It is often used in sinusitis. eHealthMe is studying from 2,774 Omnicef users. Check the latest studies of Omnicef.

What is Robitussin?

Robitussin has active ingredients of guaifenesin. eHealthMe is studying from 3,532 Robitussin users. Check the latest studies of Robitussin.



On Jul, 26, 2026

14 people who take Omnicef and Robitussin together, and have interactions are studied.

Omnicef and Robitussin drug interactions.

What are the common drug interactions of Omnicef and Robitussin, by gender? *:

female:

  1. Cardiac failure congestive
  2. Dehydration (dryness resulting from the removal of water)
  3. Hypotension (abnormally low blood pressure)
  4. Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
  5. Chronic obstructive pulmonary disease (a progressive disease that makes it hard to breathe)
  6. Decreased appetite
  7. Dyspnoea exertional (breathlessness or shortness of breath)
  8. Haemorrhoids (a swollen vein or group of veins in the region of the anus)
  9. Malaise (a feeling of general discomfort or uneasiness)
  10. Pneumonia

male:

  1. Acute respiratory failure
  2. Anaemia (lack of blood)
  3. Renal failure (kidney dysfunction)
  4. Thrombophlebitis superficial (swelling (inflammation) of a superficial vein caused by a blood clot)
  5. Adverse drug reaction
  6. Anxiety
  7. Asthma
  8. Cardiac disorder
  9. Cardiomegaly (increased size of heart than normal)
  10. Cough

What are the common drug interactions of Omnicef and Robitussin, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

  1. Ear pain
  2. Pyrexia (fever)

10-19:

n/a

20-29:

  1. Anxiety
  2. Asthma
  3. Cardiomegaly (increased size of heart than normal)
  4. Cough
  5. Drug abuse
  6. Drug dependence
  7. Hepatosplenomegaly (enlargement of both the liver and the spleen)
  8. Insomnia (sleeplessness)
  9. Intervertebral disc protrusion (spinal disc protrusion)
  10. Ligament sprain (ligament stretched)

30-39:

n/a

40-49:

  1. Chronic kidney disease
  2. Gastrooesophageal reflux disease (stomach contents (food or liquid) leak backwards from the stomach into the oesophagus)
  3. Nephrogenic anaemia (anaemia due to kidney disease)
  4. Renal failure (kidney dysfunction)

50-59:

n/a

60+:

  1. Cardiac failure congestive
  2. Dehydration (dryness resulting from the removal of water)
  3. Renal failure acute (rapid kidney dysfunction)
  4. Blood pressure systolic increased
  5. Carotid artery stenosis (narrowing of carotid artery)
  6. Cholelithiasis (the presence or formation of gallstones in the gallbladder or bile ducts)
  7. Contusion (a type of hematoma of tissue in which capillaries)
  8. Dyspepsia (indigestion)
  9. Excoriation (to tear or wear off the skin of)
  10. Fatigue (feeling of tiredness)

What are the existing conditions these people have? *

  1. Pain: 3 people, 21.43%
  2. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 3 people, 21.43%
  3. High Blood Pressure: 3 people, 21.43%
  4. Chest Pain: 2 people, 14.29%
  5. Metastatic Renal Cell Carcinoma (spreadable kidney cell tumour): 2 people, 14.29%
  6. Wheezing (a high-pitched whistling sound made while you breath): 1 person, 7.14%
  7. High Blood Cholesterol: 1 person, 7.14%
  8. Blood Cholesterol Decreased: 1 person, 7.14%
  9. Cough: 1 person, 7.14%
  10. Emphysema (chronic respiratory disease - over inflation of the air sacs (alveoli) in the lungs): 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Omnicef and Robitussin?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Omnicef and Robitussin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Omnicef:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Robitussin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Omnicef and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Robitussin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on cefdinir and guaifenesin (the active ingredients of Omnicef and Robitussin, respectively), and Omnicef and Robitussin (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: